Press Releases

Press Releases

Nov 09, 2026

CRISPR Therapeutics Presents Phase 1b Data for CTX310® Demonstrating Reductions in ANGPTL3 and Triglycerides in Patients with Severe Hypertriglyceridemia at the American Heart Association (AHA) Scientific Sessions 2026

Nov 08, 2026

CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune Diseases

Nov 04, 2026

CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition

Nov 02, 2026

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results

Nov 02, 2026

CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer

Oct 19, 2026

CRISPR Therapeutics Announces Chief Financial Officer Transition

Oct 08, 2026

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026

Oct 02, 2026

CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026

Sep 08, 2026

CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

Aug 28, 2026

CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026

Aug 03, 2026

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

May 28, 2026

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

May 06, 2026

CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference

May 04, 2026

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

Apr 07, 2026

CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Mar 11, 2026

CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering

Mar 10, 2026

CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering

Feb 12, 2026

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Jan 12, 2026

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones

Jan 05, 2026

CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference